Pharmacogenetics of EGFR and VEGF inhibition.

Abstract excerpt

Even though treatment of several types of solid tumours has improved in the past few years with the introduction of the monoclonal antibodies against epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), response rates to these targeted therapies are modest. Pharmacogenetic factors have the potential to select patients with higher chance of response to agents that target these...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to EGFR gene
• Share to Genetic Variation
• Share to Neoplasms